CING CINGULATE INC

Cingulate to Participate in Benzinga All Live Access Event

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on August 19, 2022, at 9 a.m. CST.

The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview.

The event may be viewed live on Benzinga’s YouTube channel, , and will also be available for viewing on Cingulate’s website at .

About Cingulate® 

Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit 

Investor Relations 

Thomas Dalton 

Head of Investor & Public Relations, Cingulate



913-942-2301



Matt Kreps

Darrow Associates



214-597-8200



Media Relations

Melyssa Weible

Elixir Health Public Relations



201-723-5805



EN
15/08/2022

Underlying

CINGCINGULATE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CINGULATE INC

 PRESS RELEASE
Free
CING CINGULATE INC

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of...

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “” Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) --   (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced the efficacy results from an F...

May 20, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

FDA and Cingulate Aligned with Filing Requirements for New Drug Applic...

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provid...

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-genera...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fe...

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced positive top-line results from the CTx-1301-013 study...

April 29, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Receives $3 Million Grant from Private Foundation to Acceler...

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Technology CTx-2103 has the Potential to Reduce Use of Benzodiazepine’s and Associated Withdrawal and Dependency Issues ...

April 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch